Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2018
Jun. 30, 2018
Current assets:    
Cash $ 13,361 $ 15,934
Accounts receivable - trade 155 75
Contract assets 57 0
Prepaid expenses and other current assets 396 276
Total Current Assets 13,969 16,285
Fixed assets, net of accumulated depreciation 24,812 25,152
Intangible assets, net of accumulated amortization 1,498 1,620
Security deposits 24 26
Total Assets 40,303 43,083
Current liabilities:    
Accounts payable (related party of $79 and $189 as of December 31, 2018 and June 30, 2018, respectively) 662 790
Accrued expenses (related party of $651 and $789 as of December 31, 2018 and June 30, 2018, respectively) 1,052 1,048
Capital lease obligation – current portion 205 197
Contract liabilities 2,526 0
Total Current Liabilities 4,445 2,035
Capital lease obligation - net of current portion 24,780 24,884
Total Liabilities 29,225 26,919
Commitments and Contingencies
iBio, Inc. Stockholders' Equity:    
Common stock - $0.001 par value; 275,000,000 shares authorized; 18,836,792 and 16,040,126 shares issued and outstanding as of December 31, 2018 and June 30, 2018, respectively 19 16
Additional paid-in capital 108,188 104,408
Accumulated other comprehensive loss (30) (30)
Accumulated deficit (97,095) (88,228)
Total iBio, Inc. Stockholders' Equity 11,082 16,166
Noncontrolling interest (4) (2)
Total Equity 11,078 16,164
Total Liabilities and Equity 40,303 43,083
iBio CMO [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series A Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series B Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued $ 0 $ 0